- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Veracyte Inc (VCYT)
Veracyte Inc stock price live, this page displays NASDAQ VCYT stock exchange data. View the VCYT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Veracyte Inc real time stock price chart below.
What Is the Veracyte Inc Stock Price Today?
The Veracyte Inc stock price today is 30.34.
What Is the Stock Symbol for Veracyte Inc?
The stock symbol for Veracyte Inc is ""VCYT.""
What Stock Exchange Does Veracyte Inc Trade On?
Veracyte Inc is listed and trades on the NASDAQ stock exchange.
Is Veracyte Inc a Good Stock to Buy?
Determining whether Veracyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCYT quote. (ISIN: US92337F1075)
What Is the Veracyte Inc Stock Price Today?
The Veracyte Inc stock price today is 30.34.
What Is the Stock Symbol for Veracyte Inc?
The stock symbol for Veracyte Inc is ""VCYT.""
What Stock Exchange Does Veracyte Inc Trade On?
Veracyte Inc is listed and trades on the NASDAQ stock exchange.
Is Veracyte Inc a Good Stock to Buy?
Determining whether Veracyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCYT quote. (ISIN: US92337F1075)
Fair Value
An estimate of a Veracyte Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.79
30.69
52 wk Range
22.61
47.32
VCYT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VCYT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Veracyte Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.7930.69
52 wk Range
22.6147.32
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VCYT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Veracyte Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
39.75
Upside
+31.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Veracyte Inc Company Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of $0.44 beat $0.11 forecast; revenue of $130.2M exceeded expectations. Stock fell 4.16% after hours despite results.
- Full-year revenue guidance raised to $496-$500M. Testing volume up 15%, with Decipher prostate test showing 28% growth.
- Company ended Q2 with $320.7M cash. Plans to launch new tests for metastatic population and muscle-invasive bladder cancer.
- CEO emphasized patient-centric innovation; CFO confident in double-digit revenue growth. Analysts focused on metastatic Decipher test.
- Veracyte faces challenges in market differentiation, competition, economic uncertainty, and potential regulatory changes.
Last Updated: 07/08/2025, 08:50
Read Full TranscriptCompare VCYT to Peers and Sector
Metrics to compare | VCYT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCYTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 90.6x | −4.8x | −0.5x | |
PEG Ratio | 0.62 | −0.19 | 0.00 | |
Price/Book | 2.0x | 2.3x | 2.6x | |
Price / LTM Sales | 5.0x | 7.2x | 3.2x | |
Upside (Analyst Target) | 36.8% | 376.2% | 38.8% | |
Fair Value Upside | Unlock | −3.1% | 5.4% | Unlock |
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 39.75
(+31.02% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
0.44 / 0.11
Revenue / Forecast
130.16M / 121.10M
People Also Watch
FAQ
What Stock Exchange Does Veracyte Inc Trade On?
Veracyte Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Veracyte Inc?
The stock symbol for Veracyte Inc is "VCYT."
What Is the Veracyte Inc Market Cap?
As of today, Veracyte Inc market cap is 2.39B.
What Is Veracyte Inc's Earnings Per Share (TTM)?
The Veracyte Inc EPS (TTM) is 0.34.
When Is the Next Veracyte Inc Earnings Date?
Veracyte Inc will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is VCYT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Veracyte Inc Stock Split?
Veracyte Inc has split 0 times.
How Many Employees Does Veracyte Inc Have?
Veracyte Inc has 824 employees.
What is the current trading status of Veracyte Inc (VCYT)?
As of 31 Aug 2025, Veracyte Inc (VCYT) is trading at a price of 30.34, with a previous close of 29.95. The stock has fluctuated within a day range of 29.79 to 30.69, while its 52-week range spans from 22.61 to 47.32.
What Is Veracyte Inc (VCYT) Price Target According to Analysts?
The average 12-month price target for Veracyte Inc is USD39.75, with a high estimate of USD45 and a low estimate of USD28. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +31.02% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.